NCT00002210已完成2 期
Phase II Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Effect of Delavirdine Mesylate (Rescriptor), in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1-Infected Neonates, Infants, and Children
Pharmacia and Upjohn2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 1 Month 至 15 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •HIV infection.
- •Plasma HIV-1 levels greater than 10,000 copies/ml.
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3HIV InfectionsNCT00002123Pharmacia and Upjohn
已完成
1 期
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)HIV InfectionsNCT00000810National Institute of Allergy and Infectious Diseases (NIAID)120
已完成
不适用
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected PatientsHIV InfectionsNCT00002401Pharmacia and Upjohn160
已完成
不适用
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take ZidovudineHIV InfectionsNCT00002312Pharmacia and Upjohn
终止
1 期
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung CancerNSCLCNCT05492045InventisBio Co., Ltd22